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Abstract Aplastic anemia developed in 9 of 32 
patients (28 percent) undergoing orthotopic liver trans· 
plantation for acute non·A, non-8 hepatitis, at one to 
seven weeks after the procedure. No patient previously 
had evidence of hematologic dysfunction or condi-
tions known to be associated with aplastic anemia, No 
other cases of aplastic anemia were identified among 
1463 patients undergoing liver transplantation for ali 
other indications at the four centers participating 
in the study (chi-square = 415, P<O.001; 95 percent 
confidence interval for the incidence of aplastic anemia 
aiter transplantation for non-A, non-8 hepatitis, 13 to 
44 percent, vs, 0.00 to 0.13 percent for all other in-
dications). 
TIVER failure after severe acute or subacute hepati-
L tis is an accepted indication for orthotopic liver 
transplantation. A recent analysis of 29 patients with 
acute liver failure demonstrated that the odds in favor 
of survival were greatly increased by transplantation, 
and the causes of treatment failure did not appear to 
be different from those in patients who underwent 
transplantation for other reasons. 1-3 We present clini-
cal data on nine patients who had aplastic anemia 
after transplantation, a complication that may be 
unique to patients with acute non-A, non-B viral 
hepatitis. 
METHODS 
The records of the four cooperating liver-transplant centers (the 
University of Pittsburgh. the University of Chicago, the University 
of Texas-Southwestern, and the University of Minnesota) were 
searched to identify patients in whom aplastic anemia had been 
diagnosed after they had received a liver transplant. Nine such 
patients were identified, and investigators at each institution com· 
prehensively reviewed the hospital charts, Computerized data bases 
provided information on the total population of 1495 patients who 
had undergone liver transplantation in these four centers. The case 
of one patient has been briefly reported elsewhere! 
Patients underwent transplantation because of evidence of severe 
impairment of hepatic function, from which they were not expected 
to recover, In these patients, acute hepatitis was defined as leading 
to hepatic failure within 8 weeks, and subacute hepatitis leading to 
hepatic failure within 8 to 28 weeks. I 
A thorough medical history, which included reference to chronic 
liver disease, autoimmune disease, and exposure to hepatitis, drugs, 
or toxins, was available in each case, Serologic testing for hepatitis 
A (antibody to hepatitis A virus IgM), hepatitis B (hepatitis B 
surface antigen, antibody to hepatitis B surface antigen, core anti-
body IgM; hepatitis B e antigen, and e antibody), Epstein-Barr 
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The operative and postoperative treatment of these pa-
tients was not otherwise different, indicating that the 
aplastic anemia was a complication of the hepatitis, not of 
the transplantation procedure. Four of the nine patients 
died of complications due to infections. Three of the sur-
viving patients have been followed for less than six 
months, one for one year, and one for two years. The two 
patients followed the longest have recovered marrow 
function to an appreciable degree, and two of the others 
have evidence of early recovery, 
We conclude that patients undergoing orthotopic liver 
transplantation for non-A, non-8 hepatitis are at a high riSk/ 
for the development of aplastic anemia. (N Engl J Med 
1988; 319:393-6.) 
virus, cytomegalovirus, and herpes simplex virus was performed in 
all cases, Wilson's disease was diagnosed if low serum concentra· 
tions of ceruloplasmin and characteristic clinical findings were pres· 
ent, Non·A, non-B hepatitis was diagnosed if other causes of acute 
or subacute liver failure could be excluded. 
Aplastic anemia was defined as a profound and protracted reduc· 
tion in the concentration of blood elements derived from the bone 
marrow, which required transfusion therapy and was related to 
marked hypoplasia or aplasia of the bone marrow. 5,6 Marrow sam-
ples were cultured for bacterial, fungal, and viral pathogens. 
REsULTS 
Table I shows the characteristics of the nine pa-
tients in whom aplastic anemia developed. In each, 
the indication for transplantation was non-A, non-B 
hepatitis. All were in good health before the onset of 
hepatitis. None had a history of exposure to toxins, 
and none were receiving medication at the time of the 
onset of hepatitis. 
The source of hepatitis was not evident in any of 
these patients. None had a history of exposure to hep-
atitis. Among the patients with non-A, non-B hepatitis 
who did not become anemic, several of the adult pa-
tients did have percutaneous exposure, and the sibling 
of one child subsequently had self-limited acute hepa-
titis. One patient (No.3) had an earlier episode of 
hepatitis without serologic markers, 11 months before 
the episode that led to transplantation. 
The histopathological appearance of the liver speci-
mens was consistent with severe viral hepatitis7; mas-
sive necrosis was observed in eight specimens, and 
submassive necrosis in one. 
The hematologic values shown in Table 1 were 
those last obtained before transplantation. None of 
the patients had had prior episodes of prolonged bone 
marrow dysfunction or any condition associated with 
aplastic anemia. None had had evidence of aplastic 
anemia before the procedure, although all had re-
ceived infusions of blood products before surgery. The 
absolute neutrophil count determined before trans-
394 THE :-;'EW ENGLAND JOUR.NAL OF MEDICINE 
Table 1. Clinical Characteristics of Patients with Aplastic Anemia after 
Liver Transplantation for Non-A, Non-S Hepatitis. 
(two of aspergillus and one of can-
dida). Hepatitis developed in the 
allograft of one patient (No. 3); he 
received a second transplant, which' 
failed to function, and died while 
receiving a third. 
PRO· 
PATIENT 
No.* 
ACEI 
RACE! 
SEX 
TJME FROM 
HEPATITIS TO 
TRANSPLANT 
COMA 
GRADE 
SERUM THROMBIN HEMA-
AL Tt TIME TOCRIT 
WHITE NEUTRO- PLATE' 
BILIRUBIN CELLS PHILS+ LETS 
w~eks p..mo/llirer Ulliter 5ec % per cubic mm 
1 (UP) 10/W/M 4 III 633 
2 (UP) 7/W/F 19 1 342 
3 (UP) 20/W/M 4 !II 756 
4 (UP) 3/W/M III 653 
5 (UP) 14/W/M 4 I 426 
6 (UC) 5/B/M 3 !II 513 
7 (UC) 14/B/F 4 II 608 
8 (UT) 4/W/M 2 III 656 
9(UM) 7/B/M 9 III 547 
426 23.1 
249 14.6 
449 19.8 
88 41.6 
530 63.0 
2.685 65.0 
535 20.3 
390 36.0 
361 28.0 
37.3 6.700 
28.8 2,300 
29.6 2,900 
31.3 4.600 
36.6 4,100 
35.0 7,200 
35.0 6,400 
28.1 4.100 
29.8 11,300 
5,230 
1,240 
2,490 
3,170 
2,624 
2,880 
3.700 
3,610 
1,800 
124 
18 
130 
128 
192 
57 
372 
115 
114 
*UP denotes University of Pittsburgh. UC University of Chicago. UT University of Texas. and UM University of 
Minnesota. 
Five patients are alive at this 
writing. Patient 1 received four 
transplants. The first failed because 
of primary nonfunction, and the 
second and third because of graft 
rejection. The patient is alive and 
has normal peripheral-blood counts 
24 months after receiving the fourth 
transplant. Patient 2, at 12 months 
after transplantation, has had par-
tial recovery, with a peripheral-
tAlanine aminmransferase: to convert to microkatals per liter. multiply by 0.01667. 
IAbsolute neutrophil count «800 = low). 
plantation ranged from 1240 to 5230 per cubic milli-
meter, and the hematocrit from 28.1 to 37.3 percent. 
Thrombocytopenia occurred in three patients; in two 
patients (No.2 and 6) it could not be explained, and in 
the third (Patient 9) it was associated with a course of 
acyclovir given because of exposure to chickenpox. A 
bone marrow examination performed before trans-
plantation showed normal results in one patient (No. 
8), and an examination performed five days after 
transplantation because of transient thrombocytope-
nia demonstrated increased megakaryocytes in an-
other patient (No.6) (Table 2). 
The onset of aplastic anemia occurred 3 to 22 weeks 
after the onset of hepatitis and 1 to 7 weeks after trans-
plantation (Table 2). Normal blood counts had been 
documented in all patients in the interval after trans-
plantation. These patients received various medica-
tions before the onset of aplastic anemia, and the ma-
jority had received drugs with potential toxicity to 
bone marrow. However, the pattern of administration 
and the variety of drugs that they received were in no 
way unusual for transplant recipients in these centers. 
Bone marrow cultures - first obtained after the onset 
of aplastic anemia in seven patients, before transplan-
tation in one, and in the interval between transplanta-
tion and the onset of aplastic anemia in one - were 
negative in all cases. 
The treatment of the patients and their outcomes 
are shown in Table 3. The general strategy emploved 
hy all the centers was to withhold any medications 
that might have contributed to bone marrow dysfunc-
tion. Immunosuppression was discontinued or re-
duced - in principle. to reduce the risk of infection. 
Three patients iNa. t, 2, and 6) had alJograft rejec-
tion. which necessitated repeat transplantation in one. 
Five patients received preparations of antibodies di-
rected against T cells: two patients (;.Jo. t and 2) for 
the treatment of rejection. and three (No.6. 7. and 9) 
as therapy for aplastic anemia. H 
Three patients died of systemic fungal infection 
blood leukocyte count of 2000 and a 
platelet count of 20,000. He re-
quires packed red cells and platelet 
transfusion therapy. Patients 4, 5, and 7 are alive after 
short periods of follow-up. 
Table 4 shows the total experience of the participat-
ing centers with respect to the occurrence of aplastic 
anemia after liver transplantation. Aplastic anemia 
has occurred only after transplantation for non-A, 
non-B hepatitis, with a frequency of 28 percent. The 
probability that this observation is due to chance is 
minute (chi-square = 415, P<O.OOI). The 95 percent 
confidence interval for the frequency of occurrence of 
aplastic anemia after liver transplantation for non-A, 
non-B hepatitis is 13 to 44 percent, as opposed to 0.00 
to 0.13 percent for all other indications, assuming 
the occurrence of half a case in order to do the com-
putation.9 
DISCUSSION 
We found an extremely high frequency of occur-
rence (28 percent) of aplastic anemia after liver trans-
plantation was performed for the indication of acute 
non-A, non-B hepatitis. This frequency is in contrast 
to the absence of this complication among the 1463 
patients in the four cooperating centers who received 
liver transplants for all other indications, the frequen-
cy of 0.1 to 0.2 percent reported among patients with 
acute viral hepatitis who did not undergo transplanta-
tion,10-12 and the incidence of 2 to 5 per million per 
year in the general population:",6 / 
Non-A, non-B hepatitis is the most frequently diag-
nosed cause of acute hepatic failure due to hepatitis in 
our centers, accounting for 58 percent of cases. (As 
Table 4 shows, most cases of liver failure are not due 
to hepatitis.) Although several patients in the series 
had percutaneous exposure to hepatitis - through a 
transfusion. for example, or a needle stick - none of 
those who had aplastic anemia did. Sporadic nOli-A, 
non-B hepatitis remains a poorly defined entity. diag-
nosed when the patient appears to have viral hnatitis 
and serologic testing is negative for known agenls. It is 
necessarily a diagnosis of exclusion, which requires an 
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Table 2, Clinical Data Related to Aplastic Anemia. 
PATIEt"r 
No. 
I (UP) 
2 (UP) 
3 (UP) 
4 (UP) 
5 (UP) 
6 (UC) 
FROM 
ONSET OF 
ANEMIA 
FROM 
HEPATITIS TRANSPLANT 
weeks 
6 
22 
5 
10 7 
7 
10 7 
10 6 
12 
HEMA- WHITE NEUTRO- RETJCl:· PLUE-
TOCRIT CELLS'" PHILS" LOCYTES7 LETS'" 
'7{' per cubic mm 
23,0 700 374 IA 
20.9 600 90 ND 9 
22.9 400 160 0,8 6 
28,8 1100 720 0,8 15 
24,3 300 120 2.6 
14,0 400 0 0 10 
17,0 1100 66 0,2 7 
21.0 500 21 
° 
25 
18,0 700 63 o 12 
*Representative low values before" transfusion. 
BONE 
MAoolt~ 
Marked hypoplasia C=, 33), 
moderate hypoplasia (75), 
mild hypoplasia (90) 
Aplasia i31 ) 
Marked hypoplasia (12, 19,26) 
Marked hypoplasia (55) 
Marked hypoplasia (43) 
Normocellularity (5), 
marked hypoplasia (45), 
aplasia (59) 
Marked hypopiasia (55) 
Nonnocellularity (preop-
erative), marked hypo-
plasia (II), moderate 
hypoplasia (25) 
Marked hypoplasia (39) 
MEDICATIONS BEFORE 
APLASTIC ANBRl. 
Cyclosporine, conicosteroid. celotaxlme, 
cimelidine, captopril 
Cyclosporine, conicosteroid, cefotaxime, 
furosemide, ampicillin, aspirin, 
dipyridamole, hydralazine 
Cyclosporine, conicosteroid, cefotaxime, 
ampicillin, clonidine, furosemide 
Cyciosporine, conicosteroid, cefotaxime, 
ranitidine, furosemide, ampicillin, captopril, 
hydralazine, nifedipine, metaclopramide 
Cyciosporine, conicosteroid, cefotaxime, 
furosemide, phenobarbital, ampicillin, 
hydralazine, captopril 
Cyciosporine, conicosteroid, cefamandole. 
hydralazine. propranolol. captopril. 
trimethoprim-sulfamethoxazole. gentamicin. 
carbenicillin. methyldopa, ranitidine 
Cyclosporine, conicosteroid, cdoxitin, 
aspirin, hydralazine, ranitidine, furosemide 
Cyclosporine, conicosteroid, amikacin, 
trimethoprim-sulfamethoxazole, nafcillin, 
vancomycin, metronidazole, amphotericin B, 
furosemide, spironolactone, hydralazine, 
captopril 
Cyclosporine, corticosteroid, azathioprine, 
chloramphenicol, amikacin, acyclovir, 
trimethoprim-sulfamethoxazole, captopril. 
propranolol, spironolactone, phenobarbital 
t Absolute neutrophil count «800 = low). Representative low values before transfusion are shown. 
t:ND denotes not detennined. Representative low values before tr.ansfusion are shown. 
§"Aplasia" indicates that blood-forming elements were absent; "marked hypoplasia," that ,hey were very scarce; "moderate hypoplasia," that they were scarce: and "mild hypoplasia," that they 
were reduced. Values in parentheses denote days after transplantation. 
exhaustive search for other causes. 13 Non-A, non-B 
hepatitis is not rare, and seems to be more severe than 
hepatitis A or B. In one series, it accounted for 25 
percent of the cases of fulminant viral hepatitis ·in 
which Grade IV encephalopathy developed among 
453 patients with acute hepatic failure. H In other se-
ries, it was the diagnosis in 26 of 31 children with 
fulminant hepatitis 15 and in 32 of 73 young adults 
with fulminant viral hepatitis.16 Its mortality rate is 
the highest among the rates for all causes of acute liver 
failure, which accounts for its frequency among pa-
tients referred to our centers for transplantation, 
In our experience, the only patients in whom aplas-
tic anemia developed after liver transplantation had 
sporadic non-A, non-B hepatitis, Few data have been 
reported on the occurrence of aplastic anemia among 
patients with non-A, non-B hepatitis and acute hepat-
ic failure, perhaps because few patients survive long 
Table 3. Treatment of Aplastic Anemia and Outcome, 
PATIENT 
No, 
I (UP) 
2 (UP) 
3 (UP) 
4 (UP) 
5 (UP) 
6(UC) 
7 (UC) 
8 (UT) 
9(UM) 
. ANTILYMPHOCYTE THERAPY* 
Polyclonal ALG, 40 mg/kg/day for 14 days 
Monoclonal OKT3, 0,12 mg/kg/day 
None 
None 
None 
Polyclonal A TG. 12 mg/kg/day for 10 days 
Polyclonal A TG. 10 mg/kg/day for 10 days 
None 
Polyclonal A TG, 15 mg/kg/day for 5 days 
OUTCOME 
SUrvival wim horinal marrow function and 4th graft, after primary non-
function of 1st graft and rejection of 2nd and 3rd gmfts (follow-up, 2 yn 
Survival with partial recovery of marrow function (follOW-Up, I yr) 
Death during receipt of 3rd graft, after development of hepatitis in 1st 
graft and primary non function of 2nd graft 
Survival with some recovery of marrow function (follow-up, <6 mol 
Survival with some recovery of marrow function (follow-up. <6 mOl 
Death due to disseminated candida, intestinal hemorrhage 
Survival with no recovery of marrow function (follow-up, <6 mol 
Death due to systemic aspergillosis 
Death due to systemic aspergillosis 
'Al.G denotes polyclonal antilymphocyte globulin, OKT3 monoclonal anti-OKT3 (Orthoclane OKT-3, Orthol, and ATG polyclonal an,ithymocyte globulin (Atgam. Upjohn), 
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Table 4. Occurrence of Aplastic Anemia, According to Indication 
for Orthotopic Liver Transplantation. 
APLASTIC 
ANEMIA 
Yes 
No 
9 
23 
32 
INDICATION FOR TRANSPLANTATION 
ACUTE HEPAnTIS 
A or B nonvira'* 
number of patients 
o 
12 
12 
o 
22 
22 
OTHER THAN 
HEPATITIS 
o 
1429 
1429 
. "Hepatitis induced by drugs (18 patients) or due to Wilson's disease (4 patients). 
TOTAL 
9 
1486 
1495 
enough for this complication to develop. Although 
aplasti~ anemia is a complication in fewer than 2 per 
1000 cases of typical non-A, non-B hepatitis,17-19 13.4 
percent of cases of acquired aplastic anemia were pre-
ceded by non-A, non-B hepatitis in one large series.2o 
In another series, of 31 children with fulminant hepat-
ic failure, 2 had aplastic anemia and 2 others had 
prolonged t!lrombocytopenia; all these patients had 
sporadic non~AI non-B hepatitis. IS The frequency,of 
the occurrence of aplastic anerriia in our series is high-
er than in any previous report. It seems possible that 
successful transplantation simply permitted the fre-
querit e.xpression of aplastic anemia, which was pre-
cluded by a death rate that approached 90 percent in 
other s'eriesY Furthermore, it cari be concluded that 
aplastic anemia is not a complication of liver failure. 
It was not a complication of the course in other 
patients with equal degrees of hepatic compromise, 
and in the majority of patients described here, liver 
function was normal when aplastic anemia became 
evident, 
We could not discern any differences in the tech-
nique of transplantation, the drugs used in the postop-
erative period, or the types or severity of complica-
tions that distinguish these patients. 
The high mortality rate ascribed to hepatitis-associ-
ated aplastic anemiaS,6,1 i,20 has not been observed in 
our patients, but the follow-up period has been short. 
With longer observation, a better assessment can be 
made of the effect of this complication on survival and 
the need for intervention with therapies such as bone 
marrow transplantation. 
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